Navigation Links
Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
Date:12/4/2007

us diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "expect"; "potential"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of MDX-1342 in patients, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006
'/>"/>

SOURCE Medarex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  There is still ... organization,s success. The 10th Annual Institute for Supply ... for Excellence in Supply Management is open for ... the understanding and importance of supply management by ... and best supply management practices.  Entries are due ...
(Date:7/30/2014)... Mich. , July 30, 2014 Advanced Photonix ... quarter (ending June 27, 2014) financial results on Monday, August ... be released after the close of the market and the ... the results at 4:30 p.m. EDT on the same day. ... Kurtz (CEO and Director), Rob Risser (COO ...
(Date:7/30/2014)... Inc. (NASDAQ: HOLX ) today announced its ... 2014. Third Quarter Financial Highlights and Recent ... reflecting operational growth of 0.5% and a positive currency ... the prior year. , Revenues grew in three ... grew 3.5%. , GYN Surgical revenues grew 3.5%. ...
Breaking Medicine Technology:Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17
... findings presented today show that CONCERTA® (OROS® methylphenidate ... medication with data that demonstrate a significant treatment ... 12.5 hours in children with Attention Deficit Hyperactivity ... medical condition characterized by inattention, hyperactivity and impulsivity(1) ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced unaudited financial results for the three months ended ... September 30, 2009 , As of September 30, ... equivalents and an additional $50.9 million in investment securities, ...
Cached Medicine Technology:CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 2CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 3CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 4CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 5CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 6CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/30/2014)... 30, 2014 Nationally recognized leader in ... who since September 2013 has served as president of ... new dean of the College of Nursing at University ... her leadership of the NLN, as the nation's premier ... academic nursing and research institutions in the country. ...
(Date:7/30/2014)... Daily Gossip mentions that the "Panic Away" ... way to stop anxiety and eliminate all associated symptoms. It ... less than 150,000 people in getting their lives back. , ... anxiety treatment system that will teach sufferers different techniques on ... very simple to access, as it is available in a ...
(Date:7/30/2014)... Within weeks freshman will begin to pour onto ... this will be a time of growth and the start to ... it may not be as easy as it looks. Some ... their major at least once and many will switch two or ... costs are exacerbated when switching in the later years of college. ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... July 30, 2014 Throughout the month ... with free oral cancer screenings. Using a new technological ... to detect the disease in its early stages. , ... cheek, mouth, sinuses, throat and other areas in and ... Surveillance, Epidemiology, and Ends Results (SEER) program, 30 percent ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2
... , MANCHESTER, N.H., Aug. 18 Anthem Blue Cross ... offer coverage for the administration of the H1N1 (swine flu) vaccine ... administration will be covered for members whose benefit plans provide coverage ... coverage of seasonal flu vaccine administration for those whose health plans ...
... , , , ... premier health information network, today announced its partnership with Blue ... in health care and reduce the cost of care administration ... Network to support the secure exchange of administrative health information ...
... , SAN FRANCISCO, Aug. 18 ... determine taste and smell, has been awarded $750,000 by the ... expertise to asthma by defining the nerves that contract the ... severity of these episodes. , , ...
... , , ... the country,s premier Medicare-based software, consulting and education solutions ... America,s Health Insurance Plans (AHIP) Medicare and Medicaid Conference ... D.C. The conference will focus on the leading concerns ...
... , , ATLANTA, ... company providing risk, cost and care management solutions, recently signed a ... on the needs of Taft-Hartley Organizations and public employees, representing approximately ... considered and evaluated a number of legacy vendors within the marketplace ...
... , , , ... report from market research firm KLAS*, Siemens Healthcare,s SOMATOM(R) ... systems . Powerful and cost-effective, the SOMATOM Emotion ... brain, chest, and abdomen examinations, but also undertake high-end, detailed examinations, ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 2Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 3Health News:$750,000 Awarded for Cutting-Edge Research to Reduce the Severity of Asthma Attacks 2Health News:Burgess(TM) to Sponsor and Present at the 2009 AHIP 'Medicare & Medicaid' Conference 2Health News:Union HealthShare Signs Multi-Year, Multi-Million Dollar Agreement with North Star Health 2Health News:Union HealthShare Signs Multi-Year, Multi-Million Dollar Agreement with North Star Health 3Health News:Siemens Emotion CT Receives Top Rating in KLAS Report 2Health News:Siemens Emotion CT Receives Top Rating in KLAS Report 3
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Medicine Products: